Back

Improvement of symptoms and quality of life in patients with coronary vasomotion disorders by endotype-based drug therapy

27 August 2023 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Ischaemia without obstructive disease Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Peter Ong

Robert Bosch Hospital, Stuttgart (Germany)

6 More presentations in this session

Presentation thumbnail
Myocardial microvascular dysfunction in asymptomatic patients with hereditary dyslipidemia
Doctor T. Wodaje (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes of patients with ischemia and no obstructive coronary artery disease (INOCA) - a systematic review and meta-analysis
Doctor N. Odanovic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Coronary vasomotor disorders in ANOCA patients: insights from the CADOSA registry.
Ms S. La (Adelaide, AU)
Abstract Slides Video
Presentation thumbnail
Resting and stress coronary flow velocity for identification of different endotypes and risk classes in ANOCA patients beyond coronary flow velocity reserve
Doctor N. Gaibazzi (Parma, IT)
Abstract Slides Video
Presentation thumbnail
Impact of chronic kidney disease on the association of vascular endothelial growth factor D with cardiovascular mortality in patients with suspected or known coronary artery disease: the ANOX study
Professor K. Hasegawa (Kyoto, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Ischaemia without obstructive disease

The Event

Event poster

ESC Congress 2023

27 August 2023 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Long-term efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders
thumbnail
Congress Presentation
Coronary vasomotor disorders in ANOCA patients: insights from the CADOSA registry.
thumbnail
Congress Presentation
Targeted medical treatment based on specific endotype defined by intracoronary physiology testing leads to rapid improvement of quality of life in symptomatic patients with INOCA

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources